Small Cell Lung Cancer – Fast Track Designation to Onivyde
Background The FDA granted fast track designation to Onivyde injection for the treatment of patients with Small Cell Lung Cancer, SCLC, who progressed following a
Ovarian Cancer – Fast Track Designation to GEN-1 Immunotherapy
Background Women with advanced ovarian cancer have limited treatment options in the standard of care and therefore they have much better chances and hope in
What is a “Compassionate Drug”?
A Compassionate Drug is a new drug. So, first of all one needs to know that a Compassionate Drug is a new drug. The newest
Gastric Cancer – Bemarituzumab Plus Chemo Improves Outcomes
Background Gastric cancer has a new target to attack: FGFR2b. Anew drug, “Bemarituzumab”, targets FGFR2b. When Bemarituzumab was given with chemotherapy, the combination postponed the
Colorectal cancer – Onvansertib, a Novel Oral PLK1 Inhibitor
Background On average, KRAS is mutated in approximately 50% of patients with colorectal cancer. Chemotherapy in combination with targeted drugs is standard of care option
Melanoma – Combining Remicade or Cimzia might be better
Background Melanoma is a serious form of skin cancer that begins in cells known as melanocytes. Melanoma is dangerous because it can rapidly spread to
Metastatic Breast Cancer – Utidelone plus Xeloda prolong life
Background Patients with advanced or metastatic breast cancer have very few effective treatment options. The lack of successful therapeutic strategies is reflected by a low
Glioblastoma – A new kid on the block, MDNA55
Background – Glioblastoma and MDNA55 The interleukin-4 receptor–targeted immunotherapeutic MDNA55 has demonstrated improved survival and disease control in patients with recurrent Glioblastoma who are treated
Glioblastoma – Is Keytruda combined with Virus the future?
Background A Phase 2 multi-center study was conducted to evaluate the virus, DNX-240, also called Tasadenoturev, in combination with the immunotherapy, Keytruda, in pateints with
Advanced Sarcoma – Keytruda plus Adriamycin
Background Anthracyclines is a class of drugs used in cancer chemotherapy. A wildly used Anthracycline drug is Doxorubicin also known as Adriamycin. These drugs are
Liver Cancer – Camrelizumab plus Rivoceranib show promise
Background This clinical trial assessed the efficacy and safety of Camrelizumab plus Rivoceranib in patients with advanced liver cancer. Camrelizumab is anti-PD-1 immunotherapy drug given
